# Jolanta Kunikowska

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5953385/publications.pdf

Version: 2024-02-01

| 87 | 2,171 | 279798 23 | 254184 43 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 96 | 96 | 96 | 2105 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18Fâ€“DOPA. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1588-1601. | 6.4 | 319 |
| 2 | The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1932-1947. | 6.4 | 228 |
| 3 | Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1788-1797. | 6.4 | 211 |
| 4 | Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. European Journal of Cancer, 2021, 146, 56-73. | 2.8 | 120 |
| 5 | Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with 213Bi-substance P analogue. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1636-1644. | 6.4 | 75 |
| 6 | Safety and efficacy of targeted alpha therapy with 213Bi-DOTA-substance P in recurrent glioblastoma. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 614-622. | 6.4 | 69 |
| 7 | What parameters from 18F-FDG PET/CT are useful in evaluation of adrenal lesions?. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 2273-2280. | 6.4 | 49 |
| 8 | 68Gaâ€“Prostate-Specific Membrane Antigen-11 PET/CT. Clinical Nuclear Medicine, 2020, 45, 11-18. | 1.3 | 48 |
| 9 | Long-term results and tolerability of tandem peptide receptor radionuclide therapy with 90Y/177Lu-DOTATATE in neuroendocrine tumors with respect to the primary location: a 10-year study. Annals of Nuclear Medicine, 2017, 31, 347-356. | 2.2 | 47 |
| 10 | Semiquantitative Analysis and Characterization of Physiological Biodistribution of 68Ga-DOTA-TATE PET/CT. Clinical Nuclear Medicine, 2012, 37, 1052-1057. | 1.3 | 43 |
| 11 | Zalecenia ogÃ³lne dotyczÄ…ce postÄ™powania w nowotworach neuroendokrynnych ukÅ‚adu pokarmowego (rekomendowane przez PolskÄ… SieÄ‡ GuzÃ³w Neuroendokrynnych). Endokrynologia Polska, 2014, 64, 418-443. | 1.0 | 42 |
| 12 | Zalecenia ogÃ³lne dotyczÄ…ce postÄ™powania diagnostyczno-terapeutycznego w nowotworach neuroendokrynnych ukÅ‚adu pokarmowego (rekomendowane przez PolskÄ… SieÄ‡ GuzÃ³w) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 297 | 1.0 | 41 |
| 13 | Repeated cycles of peptide receptor radionuclide therapy (PRRT) â€“ Results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET. Radiotherapy and Oncology, 2012, 102, 45-50. | 0.6 | 39 |
| 14 | Statins Impair Glucose Uptake in Tumor Cells. Neoplasia, 2012, 14, 311-323. | 5.3 | 37 |
| 15 | [68Ga]Ga-PSMA Versus [18F]PSMA Positron Emission Tomography/Computed Tomography in the Staging of Primary and Recurrent Prostate Cancer. A Systematic Review of the Literature. European Urology Oncology, 2022, 5, 273-282. | 5.4 | 37 |
| 16 | Dosimetry in clinical radionuclide therapy: the devil is in the detail. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1-3. | 6.4 | 35 |
| 17 | 225Ac- and 213Bi-Substance P Analogues for Glioma Therapy. Seminars in Nuclear Medicine, 2020, 50, 141-151. | 4.6 | 34 |
| 18 | Tumor uptake in glioblastoma multiforme after IV injection of [177Lu]Lu-PSMA-617. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1605-1606. | 6.4 | 31 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Tandem peptide receptor radionuclide therapy using 90Y/177Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter experience. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 922-933. | 6.4 | 31 |
| 20 | Targeted Î±-Emitter Therapy of Neuroendocrine Tumors. Seminars in Nuclear Medicine, 2020, 50, 171-176. | 4.6 | 30 |
| 21 | Glioblastoma multiforme: another potential application for 68Ga-PSMA PET/CT as a guide for targeted therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 886-887. | 6.4 | 29 |
| 22 | Diagnostic Performance and Clinical Impact of <sup>68</sup>Ga-PSMA-11 PET/CT Imaging in Early Relapsed Prostate Cancer After Radical Therapy: A Prospective Multicenter Study (IAEA-PSMA Study). Journal of Nuclear Medicine, 2022, 63, 240-247. | 5.0 | 28 |
| 23 | Elevated D-dimer concentration identifies patients with incomplete recanalization of pulmonary artery thromboemboli despite 6Âmonths anticoagulation after the first episode of acute pulmonary embolism. Thrombosis Research, 2008, 122, 21-25. | 1.7 | 25 |
| 24 | Nowotwory neuroendokrynne jelita cienkiego i wyrostka robaczkowego â€" zasady postÄ™powania (rekomendowane przez PolskÄ... SieÄ‡ GuzÃ³w Neuroendokrynnych). Endokrynologia Polska, 2014, 64, 480-493. | 1.0 | 25 |
| 25 | Optimizing Somatostatin Receptor Imaging in Patients With Neuroendocrine Tumors. Clinical Nuclear Medicine, 2017, 42, 905-911. | 1.3 | 24 |
| 26 | [68 Ga]Ga-Prostate-Specific Membrane Antigen PET/CT: a novel method for imaging patients with hepatocellular carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 883-892. | 6.4 | 24 |
| 27 | Diagnostic Accuracy of Contrast-Enhanced Computed Tomography and Positron Emission Tomography With 18-FDG in Identifying Malignant Solitary Pulmonary Nodules. Medicine (United States), 2015, 94, e666. | 1.0 | 21 |
| 28 | Nowotwory neuroendokrynne Å¼oÅ‚Ä…dka i dwunastnicy z uwzglÄ™dnieniem gastrinoma (zasady postÄ™powania) Tj ETQq0 0 0 rgBT | 1.0 | 20 |
| 29 | Nowotwory neuroendokrynne jelita grubego â€" zasady postÄ™powania (rekomendowane przez PolskÄ... SieÄ‡) Tj ETQq1 1 0.784314 | 1.0 | 20 |
| 30 | Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2300-2309. | 6.4 | 20 |
| 31 | EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy. European Urology Oncology, 2022, 5, 530-536. | 5.4 | 20 |
| 32 | Dose escalation study of targeted alpha therapy with [225Ac]Ac-DOTA-substance P in recurrence glioblastoma â€" safety and efficacy. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3595-3605. | 6.4 | 19 |
| 33 | Nowotwory neuroendokrynne jelita cienkiego i wyrostka robaczkowego â€" zasady postÄ™powania (rekomendowane przez PolskÄ... SieÄ‡ GuzÃ³w Neuroendokrynnych). Endokrynologia Polska, 2017, 68, 223-236. | 1.0 | 18 |
| 34 | Rak rdzeniasty tarczycy â€" badanie PET/CT ze znakowanymi 68Ga analogami gastryny i somatostatyny. Endokrynologia Polska, 2016, 67, 68-71. | 1.0 | 15 |
| 35 | A Frequency and Semiquantitative Analysis of Pathological 68Ga DOTATATE PET/CT Uptake by Primary Siteâ€"Dependent Neuroendocrine Tumor Metastasis. Clinical Nuclear Medicine, 2014, 39, 855-861. | 1.3 | 13 |
| 36 | Nowotwory neuroendokrynne trzustki â€" zasady postÄ™powania (rekomendowane przez PolskÄ... SieÄ‡ GuzÃ³w) Tj ETQq0 0 0 rgBT / | 1.0 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | The Safety and Efficacy of the Repeated PRRT with [90Y]Y/[177Lu]Lu-DOTATATE in Patients with NET. International Journal of Endocrinology, 2021, 2021, 1-10. | 1.5 | 12 |
| 38 | EANM position on the in-house preparation of radiopharmaceuticals. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1095-1098. | 6.4 | 12 |
| 39 | Nowotwory neuroendokrynne jelita grubego â€" zasady postÄ™powania (rekomendowane przez PolskÄ... SieÄ‡) Tj ETQq1 1 0.784314 | 1.0 | 11 |
| 40 | Nowotwory neuroendokrynne trzustki â€" zasady diagnostyki i leczenia (rekomendowane przez PolskÄ...) Tj ETQq0 0 0 rgBT /Overlock | 1.0 | 11 |
| 41 | Accuracy of FDG PET/CT in the evaluation of solitary pulmonary lesions â€" own experience. Pneumonologia I Alergologia Polska, 2014, 82, 198-205. | 0.6 | 11 |
| 42 | Nuclear medicine theranostics comes of age. Lancet Oncology, The, 2021, 22, 1497-1498. | 10.7 | 11 |
| 43 | Diagnostic Accuracy of PET/CT or PET/MRI Using PSMA-Targeting Radiopharmaceuticals in High-Grade Gliomas: A Systematic Review and a Bivariate Meta-Analysis. Diagnostics, 2022, 12, 1665. | 2.6 | 11 |
| 44 | <sup>68</sup>Ga-DOTATATE PET in juvenile angiofibroma. Future Oncology, 2016, 12, 1483-1491. | 2.4 | 10 |
| 45 | Women in nuclear medicine. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2678-2679. | 6.4 | 10 |
| 46 | Polish Experience in Peptide Receptor Radionuclide Therapy. Recent Results in Cancer Research, 2013, 194, 467-478. | 1.8 | 9 |
| 47 | Jak czÄ™sto wykrywamy przypadkowe zmiany w tarczycy w badaniu PET/CT z 68Ga-DOTATATE u pacjentÃ³w diagnozowanych z powodu nowotworu neuroendokrynnego?. Endokrynologia Polska, 2015, 66, 231-236. | 1.0 | 9 |
| 48 | Sequential delayed [18â€‰F]FDG PET/CT examinations in the pharynx. Scientific Reports, 2020, 10, 2910. | 3.3 | 7 |
| 49 | Nowotwory neuroendokrynne Å¼oÅ‚Ä…dka i dwunastnicy z uwzglÄ™dnieniem gastrinoma â€" zasady postÄ™powania (rekomendowane przez PolskÄ... SieÄ‡ GuzÃ³w Neuroendokrynnych). Endokrynologia Polska, 2014, 64, 444-458. | 1.0 | 7 |
| 50 | Expression of glutamate carboxypeptidase II in the glial tumor recurrence evaluated in vivo using radionuclide imaging. Scientific Reports, 2022, 12, 652. | 3.3 | 7 |
| 51 | Efficacy and safety of 90Y-DOTATATE therapy in neuroendocrine tumours. Endokrynologia Polska, 2011, 62, 392-400. | 1.0 | 7 |
| 52 | TheranosticsÂâ€“ present and future. Bio-Algorithms and Med-Systems, 2022, 17, 213-220. | 2.4 | 7 |
| 53 | Dosimetry for Radiopharmaceutical Therapy: The European Perspective. Journal of Nuclear Medicine, 2021, 62, 73S-79S. | 5.0 | 7 |
| 54 | Teaching nuclear medicine in the pandemicâ€"a new challenge for the faculty. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2075-2077. | 6.4 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns?. Journal of Nuclear Medicine, 2020, 61, 1094-1095. | 5.0 | 6 |
| 56 | Impact of the COVID-19 pandemic on nuclear medicine departments in Europe. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3361-3364. | 6.4 | 6 |
| 57 | Effect of Peptide Receptor Radionuclide Therapy (PRRT) with tandem isotopes â€“ [90Y]Y/[177Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on qualification [18F]FDG PET/CT in Polish multicenter experience â€“ do we need [18F]FDG. Endokrynologia Polska, 2020, 71, 240-248. | 1.0 | 6 |
| 58 | Response to comment by Aprile et al.: The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1259-1260. | 6.4 | 5 |
| 59 | Detection of clinically silent brain lesions in [18F]FDG PET/CT study in oncological patients: analysis of over 10,000 studies. Scientific Reports, 2021, 11, 18293. | 3.3 | 5 |
| 60 | Radioiodine therapy in patients with type II amiodaroneâ€'induced thyrotoxicosis. Polish Archives of Internal Medicine, 2014, 124, 695-703. | 0.4 | 5 |
| 61 | Neuroendocrine tumours of rare location. Endokrynologia Polska, 2010, 61, 322-7. | 1.0 | 5 |
| 62 | Gender issues in the nuclear medicine community: results from a survey promoted by the EANM Women Empowerment Task Force. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2106-2112. | 6.4 | 5 |
| 63 | Joint EANM, SNMMI, and IAEA Enabling Guide: How to Set up a Theranostics Center. Journal of Nuclear Medicine, 2022, 63, 1836-1843. | 5.0 | 5 |
| 64 | Ga-68-PSMA-11 PET/CT in Patients with Biochemical Recurrence of Prostate Cancer after Primary Treatment with Curative Intentâ€"Impact of Delayed Imaging. Journal of Clinical Medicine, 2022, 11, 3311. | 2.4 | 5 |
| 65 | 68Ga-PSMA PET/CT in Recurrence Prostate Cancer. Should We Perform Delayed Image in Cases of Negative 60 Minutes Postinjection Examination?. Clinical Nuclear Medicine, 2020, 45, e213-e214. | 1.3 | 4 |
| 66 | EANM Focus 3: The International Conference on Molecular Imaging and Theranostics in Neuroendocrine Tumoursâ€"the consensus in a nutshell. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1276-1277. | 6.4 | 4 |
| 67 | Radioguided surgery in patient with pancreatic neuroendocrine tumour followed by PET/CT scan as a new approach of complete resection evaluation â€" case report. Nuclear Medicine Review, 2014, 17, 108-109. | 0.5 | 4 |
| 68 | Tele NEN â€" zastosowanie telemedycyny w postÄ™powaniu w nowotworach neuroendokrynnych na przykÅ‚adzie NET uchyÅ‚ka Meckela. Endokrynologia Polska, 2018, 69, 313-317. | 1.0 | 3 |
| 69 | Different technical possibilities of post- -therapeutic tandem 90Y/ /177Lu-DOTATATE imaging. Nuclear Medicine Review, 2013, 16, 70-74. | 0.5 | 3 |
| 70 | Simultaneous breast cancer and DLBCL lymphoma â€" role of PET/CT examination with 18F-FDG and 18F-FES. Nuclear Medicine Review, 2018, 21, 113-114. | 0.5 | 3 |
| 71 | New forms of radionuclide therapy with (90)Y in oncology. Nuclear Medicine Review, 2008, 11, 5-11. | 0.5 | 3 |
| 72 | Nephrotoxicity after PRRT - still a serious clinical problem? Renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATATE and 90Y/177Lu-DOTATATE. Endokrynologia Polska, 2013, 64, 13-20. | 1.0 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Safety and Therapeutic Efficacy of 225Ac-DOTA-Substance PÂfor Therapy of Brain Tumors. Journal of Medical Imaging and Radiation Sciences, 2019, 50, S91-S92. | 0.3 | 2 |
| 74 | Gender balance in the editorial board of nuclear medicine journals. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3749-3750. | 6.4 | 2 |
| 75 | 2022 follow-up: impact of the COVID-19 pandemic on nuclear medicine departments in Europe. European Journal of Nuclear Medicine and Molecular Imaging, 0, , . | 6.4 | 2 |
| 76 | Retroperitoneal Pheochromocytoma With Thorax and Bilateral Neck Chemodectoma in Patients With Multiorgan Sarcoidosis. Clinical Nuclear Medicine, 2014, 39, e258-e262. | 1.3 | 1 |
| 77 | Myelofibrosis Pattern in 68Ga-PSMA PET/CT of a Patient With Recurrence Prostate Cancer. Clinical Nuclear Medicine, 2021, Publish Ahead of Print, . | 1.3 | 1 |
| 78 | Nietypowy przypadek przebiegu nowotworu neuroendokrynnego trzustki pod postaciÄ... przerzutu do serca â€" opis przypadku klinicznego. Endokrynologia Polska, 2014, 65, 232-239. | 1.0 | 1 |
| 79 | Liver transplantation as an option of treatment for a giant primary hepatic neuroendocrine tumour. Endokrynologia Polska, 2019, 70, 520-521. | 1.0 | 1 |
| 80 | Challenges in theragnostics. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2022, 65, . | 0.7 | 1 |
| 81 | A non-functioning pancreatic neuroendocrine tumour: a case report. Endokrynologia Polska, 2012, 63, 59-64. | 1.0 | 1 |
| 82 | Calcification as a cause of potential false-positive findings in bone scintigraphy verified with [68Ga]Ga-PSMA-11 PET/CT - a case report. Polish Archives of Internal Medicine, 2021, 131, 473-475. | 0.4 | 0 |
| 83 | A rare cause of chronic diarrhoea: a diagnosis to keep in mind. Endokrynologia Polska, 2021, 72, 187-188. | 1.0 | 0 |
| 84 | Familial SDHB gene mutation in disseminated non-hypoxia-related malignant paraganglioma treated with [<sup>90</sup>Y]Y/[<sup>177</sup>Lu]Lu-DOTATATE. Intractable and Rare Diseases Research, 2021, 10, 207-213. | 0.9 | 0 |
| 85 | The first â€œBest Paper of Nuclear Medicine Reviewâ€•session at the XIV International Congress of the Polish Society of Nuclear Medicine 28â€“30th of May 2014. Nuclear Medicine Review, 2014, 17, 121-122. | 0.5 | 0 |
| 86 | Parathyroid imaging with [99mTc]Tc-MIBI SPECT/CT â€" unexpected findings of bone marrow involvement of non-Hodgkinâ€™s lymphoma. Endokrynologia Polska, 2020, 71, 271-272. | 1.0 | 0 |
| 87 | Determination of left ventricular ejection fraction by gated 99mTc-sestamibi SPECT--correlation with coronary angiography. Acta Cardiologica, 2002, 57, 49-51. | 0.9 | 0 |